Singapore is on high alert as it closely monitors the global Nipah virus situation, especially in India, where two cases have been confirmed since December. The virus, which spreads from animals to humans, has a high fatality rate of 40-75%, causing respiratory distress and brain inflammation. With no vaccine available, Singapore is taking proactive measures to protect its population.
The Ministry of Health has issued clinical guidance to medical practitioners and conducted educational webinars for primary care doctors. They have also adjusted the Electronic Health Declaration Card for incoming travelers. Additionally, the Ministry of Manpower has disseminated precautionary health measures to migrant workers, domestic workers, employers, dormitory operators, and employment agencies.
These measures include daily temperature checks for new migrant workers who have traveled to India's West Bengal state and temperature screenings at airports for flights from affected areas. The Communicable Diseases Agency (CDA) has confirmed that no Nipah virus cases associated with the situation in Bangladesh or India have been detected in Singapore.
Local research is also underway to develop diagnostic kits and vaccines. The Programme for Research in Epidemic Preparedness and Response (PREPARE) is funded under the Research, Innovation, and Enterprise (RIE) program, involving collaborations between public and private sector institutions. The National University of Singapore, Duke-NUS, and A*STAR are conducting six research projects on Nipah virus, focusing on diagnostics, therapeutics, and vaccines.
Despite the ongoing research, Singapore is not currently in a hurry to procure vaccines, as the Nipah virus is localized and not widespread. However, the country is raising its caution and closely monitoring the situation, taking a more cautious approach compared to the COVID-19 pandemic.
In the event of a local outbreak, the Health Sciences Authority may consider an interim authorization for a vaccine, as the University of Oxford has developed a Nipah virus vaccine candidate that is currently in phase two trials in Bangladesh. However, the Nipah virus in South Asia is generally a zoonotic infection, and Singapore is taking a measured approach to ensure the well-being of its citizens.
